{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:52:21Z","timestamp":1791881541159,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaad.2025.12.030","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:31:31Z","timestamp":1767097891000},"page":"1177-1183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterization and treatment outcomes of rituximab therapy in super-responders and rituximab-refractory pemphigus patients: A single-center retrospective study"],"prefix":"10.1016","volume":"94","author":[{"given":"Zhili","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruzeng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.12.030_bib1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2025.12.030_bib2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib3","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"10.1016\/j.jaad.2025.12.030_bib4","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2025.12.030_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horv\u00e1th","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib6","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaad.2025.12.030_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int immunopharmacology"},{"key":"10.1016\/j.jaad.2025.12.030_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-4632.2012.5847.x","article-title":"Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial","volume":"52","author":"Balighi","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12763","article-title":"Rituximab therapy in pemphigus: a long-term follow-up","volume":"32","author":"Loi","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2025.12.030_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Dermato Venereologica"},{"key":"10.1016\/j.jaad.2025.12.030_bib11","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2025.12.030_bib12","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry","volume":"84","author":"Ari\u00ebns","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2025.02.063","article-title":"Characterization and treatment outcomes of biologic therapy in super-responders and biologic-refractory psoriasis patients: a single-center retrospective study in China","volume":"93","author":"Liu","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib14","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib15","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1111\/jdv.20290","article-title":"Factors associated with long-term complete remission in pemphigus patients receiving rituximab therapy","volume":"39","author":"Hsu","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.12.030_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamadermatol.2023.5679","article-title":"Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy: Follow-Up of the ritux 3 trial","volume":"160","author":"Tedbirt","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/bjd\/ljae107","article-title":"Beyond the skin: b cells in pemphigus vulgaris, tolerance and treatment","volume":"191","author":"Strandmoe","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"H\u00e9bert","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib21","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4049\/jimmunol.137.9.2835","article-title":"Defining the role of complement in experimental pemphigus vulgaris in mice","volume":"137","author":"Anhalt","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2025.12.030_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/ijdvl.IJDVL_89_19","article-title":"Identification of clinical and immunological factors associated with clinical relapse of pemphigus vulgaris in remission","volume":"86","author":"Guliani","year":"2020","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2025.12.030_bib23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1523-1747.ep12709624","article-title":"Deposition of the membrane attack complex of complement in pemphigus vulgaris and pemphigus foliaceus skin","volume":"92","author":"Kawana","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib24","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jaad.2020.12.062","article-title":"A 10-year retrospective cohort analysis of rituximab for the treatment of pemphigus in a Chinese population","volume":"85","author":"Chang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.12.030_bib25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2025.12.030_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jaad.2025.12.030_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaad.2025.12.030_bib28","article-title":"Efficacy and safety of low dose rituximab in pemphigus: an updated systematic review and meta-analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225033742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225033742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:27:03Z","timestamp":1791880023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225033742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0190962225033742"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.030","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization and treatment outcomes of rituximab therapy in super-responders and rituximab-refractory pemphigus patients: A single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}